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Abstract: Background: Aim of this study was to evaluate, in a cohort of haemodialysis patients
with atrial fibrillation (AF), the relationship between oral anticoagulant therapy (OAT)
and mortality, thromboembolic and haemorrhagic risk.
Methods: 290 patients with AF were prospectively followed-up for four years. Warfarin
and antiplatelet intake, age, dialytic age, comorbidities, CHA2DS2-VASc and
HASBLED scores were considered as predictors of hazard of death, thromboembolic
and bleeding events. In patients taking OAT, the International Normalized Ratio (INR)
was assessed and the percentage time in the Target Therapeutic Range (TTR) was
calculated.
Results: At recruitment, 134/290 patients were taking warfarin. During follow-up there
were 170 deaths, 28 thromboembolic events and 95 bleedings. After balancing for
treatment propensity, intention-to-treat analysis on OAT assumption at recruitment did
not show differences in total mortality, thromboembolic events and bleedings. As-
treated analysis, accounting for treatment switch, showed that patients taking OAT at
recruitment had a significantly lower mortality than those not taking it (HR 0.53, 95%CI
0.28-0.90, P=0.04), with a slight benefit of OAT  on thromboembolic events (HR 0.36,
95%CI 0.13-1.05, P=0.06), and a non-significant increase in bleedings. Among patients
taking OAT at recruitment, those continuing warfarin assumption had a significant
reduction in the risk of total (HR 0.28, 95%CI 0.14-0.53, P<0.001) and cardiovascular
(HR 0.21, 95%CI 0.11-0.40, P<0.001) mortality, compared to patients stopping
assumption.
Conclusions: In haemodialysis patients with AF, continuously taking warfarin is
associated with a reduction of the risk of total and cardiovascular mortality, and with a
slight decrease of thromboembolic events.
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Author Comments: Dear prof.  Gambaro, Editor in chief of Journal of Nephrology,
we are submitting you the revised version of the manuscript "Effect of oral
anticoagulant therapy on mortality in end stage renal disease patients with atrial
fibrillation: a prospective study".
We think that the comments of the reviewers allowed us to make modifications to the
manuscript that have definitely improved it.We included a copy of the manuscript with
revisions highlighted and a copy clean, to allow the Editor and the Reviewers to see
the changes made to the manuscript.
We hope that you may consider this new version of the manuscript acceptable for
publication in your journal.
My co-authors have all contributed to this manuscript and approve of this new
submission.
The results presented in this paper have not been published previously in whole or
part, except in abstract form. I have communicated with all of my co-authors and
obtained their full disclosures. A disclosure statement is also included. My co-authors
and I declare no conflicts of interest.
Sincerely,
Dr. Simonetta Genovesi
School of Medicine and Surgery, University of Milano-Bicocca
Via Cadore 48, 20900, Monza (MB), Italy
tel: +39 039 2332426
Fax: +390392332376
Email: simonetta.genovesi@unimib.it
Best regards
Simonetta Genovesi
Response to Reviewers: We thank the Reviewers for their comments that allowed us to make modifications to
the manuscript that have definitely improved it.We included a copy of the manuscript
with revisions highlighted and a copy clean, to allow the Editor and the Reviewers to
see the changes made to the manuscript.
Reviewer #1: Thank you for your submission. This is a relatively small study for this
topic, as previous studies usually have in excess of 1000 patients. The results are in
keeping with some other reports, and as such the data is not novel.
We agree with the reviewer that in the literature there are other studies on the same
topic that have recruited a larger number of patients. However, those studies were all
retrospective and / or registry studies, while ours is a prospective study, with a long
follow-up (four years) and including ad hoc information, especially on the exact time of
warfarin withdrawal and on INR values.We also think that our results(in particular as
regards data on mortality), are not completely in keeping with what reported by other
studies.
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Please kindly provide more details as to how patients were recruited into this study, by
providing a consort flow diagram
We added the patient selection flow chart as supplementary figure and we included
also the prevalence of AF in each participating center. The cohort included all
prevalent patients with AF of ten centers at 31-10-2010.
There are some major confounders which need to be addressed. Firstly the two groups
have some major differences, and ideally should be propensity matched, including
classic risk factors for stroke, residual renal function and recent echocardiographic
findings.
We agree that the two groups have some major differences, indeed we did an analysis
on the propensity to be under OAT at recruitment. In fact, we adjusted for major
confounders by the use of weights on the propensity to be under treatment. These
weights, called (stabilized) Inverse Probability of Treatment Weights (IPTW), were
computed by a multivariable logistic model on the propensity to be under OAT at
recruitment. In the new version of the manuscript we added to this model
echocardiographic findings (left ventricular ejection fraction and presence of left
ventricular hypertrophy, as suggested by reviewer 1) and peripheral artery disease (as
suggested by reviewer 2). Classical risk factors for stroke were already present
(comorbidities and CHA2DS2-VASCs score).We don’t have data about residual renal
function, but a median dialytic age of around 4 years is generally associated to a very
limited presence of patients with preserved residual renal function.As,after the addition
of new confounders, some variables remained partially unbalanced between groups
(standardized difference >10%),we also adjusted for these variables the final model.
All new information and results have been added to the Results section and tables.
Please explain how patients were censored, and whether there was a difference in
transplantation rates between the 2 groups
The study design was set up with a follow-up of 4 years. Only 13 patients (4.4%) were
lost to follow-up before the 4 years, 9 because they moved, 3 for transplantation and 1
with other (unspecified) reason. As far as transplant, the rate was similar in the two
groups: no OAT at recruitment 2/156 (1.3%), OAT at recruitment 1/134(0.8%).
Please provide a recognized co-morbidity score for patients
The median/mean Charlston Comorbidity Index adapted for end stage renal disease
(Hemmelgarn,2003, AJDK;42:125-132) was calculated for the two groups and added in
Table 1. No difference was found between the two groups
In terms of risks for gastro-intestinal hemorrhage.Please provide details of prescription
of H2 blockers, proton pump inhibitors, antacidsetc, and also NSAID use, and do the
authors have carriage rates for H.Pylori.
We have this information only in a subset of patients (n= 94 patients): 26 (28%) had a
prescription of H2 blockers, 63(67%) of proton pump inhibitors and no one of antiacid.
We do not have information in NSAID use and carriage rates for H.Pylori.
How many patients were prescribed dual anti-platelet therapy for cardiac disease
Height patients were taking dual anti-platelet therapy (only one was an OAT-yes
patient).
Please provide details whether episodes of hemorrhage were the direct cause of acute
hospital admission, or occurred during hops ital admission
Unfortunately, we did not collect information on hospital admission caused by
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
hemorrhage, but only on hospital admission for cardiovascular events.
Reviewer #2: The authors describe a prospective analysis of oral anticoagulant effects
in HD patients with atrial fibrillation.
METHODS:
- the paper lacks definitions. For example, how were clinical events and history such as
peripheral vascular disease or ischemic heart disease defined?
All definitions have been added to the manuscript (see Methods section)
- Which types of OAT were administered? Most of the time, "OAT" seems to be
synonymous with "warfarin". Please clarify.
All patients defined as OAT-yes were taking warfarin.
- I am not a statistics expert. However, simple logic would suggest that the frail patient
with a tendency for falls etc is less likely to receive oral anticoagulants in particular on a
permanent basis. Frailty in turn is one of the major mortality risk factors in HD patients
and indeed a surprising 17% of the patients is stated to have died from cachexia. How
did this major confounder enter the analyses?
We agree we the reviewer that frail patients might be less likely to receive OAT. For
this reason, at baseline of our study, we administrated to nephrologists a questionnaire
asking the reason why they did not prescribe warfarin, even if the patient had an
indication for taking it (i.e. CHA2DS2-VASc>=2). Only 1.3% of nephrologists
responded that “The patient had an unstable equilibrium and risked fallingeasily/had
already fallen once” and only 5.1% that “The patient was not reliable and compliant in
taking the therapy” (Genovesi S, et al. 2014, J Nephrol 27:187-192). Moreover, we
looked at the distribution of death from cachexia by OAT at baseline.No difference was
found between groups: 27/156 (17.3%) patients OAT-no and 22/134 (16%)patients
OAT-yes died from cachexia (12 were still taking the therapy at the time of death). In
addition, when a sensitivity analysis excluding patients who died within 6 months from
OAT withdrawal was done, mortality results remained similar. Finally, the median/mean
Charlston Comorbidity Index adapted for end stage renal disease (Hemmelgarn,2003,
AJDK;42:125-132) was not different between the two groups at recruitment ( see
revised Table 1).
RESULTS:
- a plethora of numbers renders the results section rather difficult to reduce. Please try
to limit the numbers to those that are not shown in the tables
We agree with the reviewer. All numeric data already present in the tables have been
removed from the Results section.
DISCUSSION:
- So how does OAT protect HD patients if there is no detectable effect on
thromboembolic events and at least a trend for more bleeding episodes (table 2)?
After the modifications suggested by the referees to the manuscript, the as-treated
analysis showed a borderline reduction of thromboembolic events in patients taking
warfarin. This can partly explain the mortality reduction observed in our population.
Moreover, in coronary artery disease patients with and without concomitant AF, oral
anticoagulation has been shown to protect against myocardial infarction and to be safe
and effective [ref 23, 24]. A recent study demonstrated in older adults (> 75 years) with
AF a benefit from OAT in terms of lower mortality, regardless of poor health and
functional condition [ref 25]. It’s possible that, also in HD patients, OAT might have a
positive effect not only through a reduction of thromboembolic risk. These concepts
and related references are present in the Discussion section.
Citing the Danish study on page 11 (ref. #3) may be misleading, as that study lumped
together HD, PD and transplant patients into a group called "renal replacement". I
suggest to disregard reference #3 here
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We agree with the reviewer.The study by Olesen included also peritoneal and
transplant patients and this makes it difficult to compare the results with those of other
studies. A sentence has been added to the Discussion section to clarify it.
- Limitations need to be discussed in more detail: First, only documented AF episodes
entered the analyses
We chose to include only cases of AF with a clear electrocardiographic documentation,
to be sure of the real presence of the arrhythmia.Furthermore, we have separated
different types of AF ( paroxismal, persistent, permanent) and, to do this, it was
necessary an accurate documentation.We cannot exclude that some centers were
more careful in the diagnosis of AF compared to other, especially for paroxysmal forms
that are often unrecognized.By note, the prevalence of AF in our population, compared
to that reported in the literature (Zimmerman Nephrol Dial Transplant 2012; 27:
3816–3822), suggests that we are close to the true prevalence of the arrhythmia.We
added this point in the limitation section.
Second, at a median dialytic age of around 4 years, it may be important to point out
that this is a cohort of dialysis "survivors"
In Italy the survival of dialysis patients is higher than that observed in other countries.
Our mortality data (which still show a rate of about 60% of deaths in four years of follow
up), are in line with those of the Italian Registry of Dialysis and Transplantation, RIDT
(http://ridt.sinitaly.org/web/eventi/RIDT/index.cfm).
If the referee considers it necessary, we can include a sentence on this point in the
manuscript.
Third, the issue of frailty (seeabove)
As reported in the limitation section we recognize that as-treated analysis might be
subject to selection bias due to adverse events causing warfarin withdrawal. Those
patients who succeeded in continuing to take the therapy could be the ones who were
less frail and had a better compliance. However, to assess this assumption, we
performed a sensitivity analysis in which we censored patients who died within six
months of warfarin withdrawal and we obtained similar results ( see Results section
and limitations).
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Effect of oral anticoagulant therapy on mortality in end stage renal disease patients with 
atrial fibrillation: a prospective study 
 
 
ABSTRACT 
Background: Aim of this study was to evaluate, in a cohort of haemodialysis patients with 
atrial fibrillation (AF), the relationship between oral anticoagulant therapy (OAT) and 
mortality, thromboembolic and haemorrhagic risk. 
Methods: 290 patients with AF were prospectively followed-up for four years. Warfarin and 
antiplatelet intake, age, dialytic age, comorbidities, CHA2DS2-VASc and HASBLED scores 
were considered as predictors of hazard of death, thromboembolic and bleeding events. In 
patients taking OAT, the International Normalized Ratio (INR) was assessed and the 
percentage time in the Target Therapeutic Range (TTR) was calculated. 
Results: At recruitment, 134/290 patients were taking warfarin. During follow-up there were 
170 deaths, 28 thromboembolic events and 95 bleedings. After balancing for treatment 
propensity, intention-to-treat analysis on OAT assumption at recruitment did not show 
differences in total mortality, thromboembolic events and bleedings. , while Aas-treated 
analysis, accounting for treatment switch, showed that patients taking OAT at recruitment had 
a significantly lower mortality than those not taking it (HR 0.531, 95%CI 0.289-0.9089, 
P=0.042), with a.  slight No benefit of OAT was evident on thromboembolic events (HR 0.36, 
95%CI 0.132-1.05, P=0.06)  ,  while and a non-significant increase in bleedings was observed 
. Among patients taking OAT at recruitment, those continuing warfarin assumption had a 
significant reduction in the risk of total (HR 0.28, 95%CI 0.14-0.53, P<0.001) and 
cardiovascular (HR 0.21, 95%CI 0.11-0.40, P<0.001) mortality, compared to patients 
stopping assumption.  
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Conclusions: In haemodialysis patients with AF, continuously taking warfarin is associated 
with a reduction of the risk of total and cardiovascular mortality, and with a slight while it is 
not associated with  a decrease of thromboembolic events. 
 
 
KEYWORDS: warfarin, haemodialysis, atrial fibrillation, mortality, stroke, bleeding  
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INTRODUCTION 
Data on the risk/benefit ratio of warfarin in patients with atrial fibrillation (AF) and end stage 
renal disease (ESRD) continue to be inconclusive, despite the high prevalence of the 
arrhythmia in this population. Some authors report an increased risk of complications derived 
from the use of oral anticoagulant therapy (OAT) in haemodialysis (HD) patients with AF, 
without any benefit in terms of thromboembolic risk protection [1, 2]. Other studies are less 
negative [3, 4] but a big uncertainty remains on how to approach these patients [5]. One major 
problem is the lack of prospective and randomized data. In fact almost all published studies 
are based on retrospective analyses of registry data. Recently a large retrospective study 
showed that warfarin was associated with a reduced mortality in a cohort of HD patients with 
newly diagnosed AF [6]. This study accounted for confounding by indication with propensity 
score, but being a register study not all potential confounders were available, in particular 
International Normalized Ratio (INR) was missing and OAT assumption was based on the 
prescription. We set a prospective study in a population of HD patients with AF, where 
information on the exact time of the possible withdrawal of warfarin and on the INR values in 
subjects taking OAT were collected, over the baseline characteristics of patients. Preliminary 
results on two years of follow-up indicated that warfarin significantly increased the incidence 
of bleeding without reducing thromboembolic events. Furthermore, the study suggested the 
presence of a trend towards a better survival in patients receiving OAT [7]. However, those 
early results needed to be completed with a long-term efficacy and safety evaluation of 
warfarin assumption. 
The main purpose of the present study was to evaluate prospectively, in a cohort of patients 
with ESRD and AF followed-up for four years, the relationship between OAT and mortality, 
thromboembolic and haemorrhagic risk .We evaluated long-term efficacy and safety of OAT 
using a causal method approach to limit the confounding by indication and to account for the 
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updated value of confounders/variables over the follow-up. Secondary aim was to test the 
predictive value of the CHA2DS2-VASc and HASBLED scores on mortality, thromboembolic 
and haemorrhagic events, given that these scores are indicated by the Cardiology Guidelines 
to identify patients at increased thromboembolic and haemorrhagic risk [8], but were 
developed in cohorts of patients in which HD was an exclusion criterion.  
 
SUBJECTS AND METHODS 
All patients alive and under observation in 10 Italian dialysis centers on 31/10/2010 were 
considered (n=1529) and their clinical charts revised for eligibility to the study. Peritoneal 
dialysis patients were not included. All subjects with at least one documented paroxysmal 
(self-terminating) or persistent (required termination by pharmacological or electrical 
cardioversion) AF episode, or with permanent AF (when there has been a joint decision by the 
patient and clinician to cease further attempts to restore and/or maintain sinus rhythm) were 
recruited, for a total of 290 patients (see Supplementary figure 1).  
At recruitment  data were collected on the presence of hypertension (systolic blood pressure 
≥140mmHg and/or diastolic blood pressure ≥90mmHg before the beginning of the HD 
session or anti-hypertensive drugs administration), diabetes mellitus, peripheral artery disease 
(clinical presence of claudication and/or evidence of significant stenosis of main arterial 
trunks by doppler examination), ischemic heart disease (previous myocardial infarction or 
coronary revascularization procedures and/or previous hospitalization due to acute coronary 
syndrome), heart failure (presence of left-ventricular dysfunction-  (left-ventricular ejection 
fraction<50%)- and/or previous hospitalization due to acute or chronic heart failure), previous 
strokes (ischemic or haemorrhagic defined by computed tomographic scan or nuclear 
magnetic resonance), and major bleeding episodes (haemorrhagic episode requiring 
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hospitalization or blood transfusion, or causing a haemoglobin plasma level reduction > 2g/dl) 
and on administration of antiplatelets and anticoagulants [7]. 
Cardiac ultrasound examination was performed in all the patients during the mid-week 
dialysis interval. Collected echocardiography data were: left ventricular ejection fraction 
(LVEF, %) and the presence of left ventricular hypertrophy (LVH), which was defined as left-
ventricular mass normalized for body surface area >125 g/m2 according to the Penn-cube 
formula, or when its presence was described in the report. 
Patients were prospectively followed-up for four years (until 31/10/2014 or death) and their 
clinical charts were updated at each dialysis session. The new onset of permanent AF, stroke 
(ischemic or haemorrhagic defined by computed tomographic scan or nuclear magnetic 
resonance), bleeding (haemorrhagic episode requiring hospitalization or blood transfusion, or 
causing a haemoglobin plasma level reduction > 2g/dl), cardiovascular events (ischemic and 
heart failure episodes that required hospitalization), and antiplatelet and anticoagulant 
treatment modifications were recorded. 
In patients taking OAT, the INR values were assessed at least once a month and the 
percentage time in the target INR range (Target Therapeutic Range, TTR) was calculated [9]. 
Only one center referred patients to a Thrombosis Clinic, while in the others the nephrologist 
took care of warfarin dosage (the policy was to keep INR between 2 and 3). 
Thromboembolic and haemorrhagic risk was calculated using the CHA2DS2-VASc and 
HASBLED score, respectively [8].  
Procedures were performed according to the Helsinki declaration for ethical treatment of 
human subjects and approved by the local ethical committee. Informed consent was obtained 
from the enrolled subjects. 
Statistical methods 
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All data were centrally revised. Patients were considered under OAT at recruitment if taking 
OAT at 31/10/2010. Rates of mortality, thromboembolic and haemorrhagic events were 
computed for patients on and not on OAT at recruitment and compared by the Poisson model.  
Marginal structural models  
In order to evaluate the effect of OAT on mortality, thromboembolic and haemorrhagic risk, 
we created a pseudo-population (that mimics a randomized trial) which mitigates the selection 
bias in OAT treatment assignment at recruitment [10]. This pseudo-population, created by the 
use of (stabilized) Inverse Probability of Treatment (and censoring) Weights (IPTW), is called 
the “IPTW cohort”. IPTW were computed by a multivariable logistic model on the propensity 
to be under OAT at recruitment that included age, diabetes mellitus, ischemic and 
bleeding/haemorrhagic strokes, ischemic heart disease, CHA2DS2-VASc and HASBLED 
score, type of AF, left ventricular ejection fraction <50% and left ventricular hypertrophy  
(and their first degree interactions), gender, dialytic age, hypertension, heart failure, 
peripheral artery disease  and antiplatelet therapy. gender, age, dialytic age, hypertension, 
diabetes mellitus, ischemic and bleeding/haemorrhagic strokes, heart failure, CHA2DS2-VASc 
and HASBLED score, antiplatelet therapy and type of AF. In order to evaluate the balance 
induced by these weights, the confounders among patients under OAT and not in this pseudo-
population were compared by standardized differences [11]. Furthermore, an inverse 
probability of censoring weight was also applied to account for loss to follow-up and 
informative censoring due to death when analysing thromboembolic and haemorrhagic 
outcomes. Final weights were computed as the product of the stabilized weights [10] for 
treatment and censoring (trimming was not necessary as weights ranged between 0.5 to 9.5). 
The weighted Cox regression model with robust standard error was applied to the IPTW 
cohort to assess the effect of OAT administration at recruitment on different relevant 
endpoints. The model was adjusted for each covariate which after balancing (IPTW cohort) Formatted: English (United States)
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still showed a standardized difference greater than 10% between the two groups (i. e. 
bleeding/haemorrhagic stroke and permanent AF). We did not add any covariate in this 
model, since all observed confounders were balanced in the IPTW cohort by the weighting 
procedure. Results of the Cox models are expressed in terms of estimated hazard ratios (HR), 
95% confidence intervals (95%CI) and P-values. 
In analogy to a randomized trial, two analyses were performed: intention-to-treat (ITT) and 
as-treated (AT) analyses. In the first one, the treatment (OAT) classification at recruitment 
was retained for the whole follow-up, while in the AT analysis patients who switched 
treatment were artificially censored (this artificial censoring was also considered in the 
inverse probability of censoring weights). 
Sequential Cox 
In order to better evaluate the effect of the time dependent variables, including OAT 
assumption, on the risk of mortality, thromboembolic and haemorrhagic events, we evaluated 
the effect of stopping OAT by the sequential Cox approach [12]. This method mimics several 
randomized controlled trials, based on individuals stopping OAT in time intervals (of one 
month), and obtains an overall treatment effect estimate. We adjusted for gender and the 
updated values (at the beginning of each month) of age, percentage of TTR ,CHA2DS2-VASc 
and HASBLED scores, presence of permanent AF and use of antiplatelets. 
The effect of suspending OAT was also estimated stratifying according to TTR > or <60% 
[13]. As it was possible that some patients had discontinued therapy because in terminal 
conditions, a sensitivity analysis was performed, in which we censored patients died within 
six months of warfarin withdrawal.  
 
Score analysis 
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The Kaplan-Meier estimator was used to describe survival in subgroups defined according to 
CHA2DS2-VASc and HASBLED scores at recruitment. We also computed rates of mortality, 
thromboembolic and haemorrhagic events by the updated value of the scores during follow-
up. 
Analyses were carried out by means of the statistical software SAS v.9.4 (SAS Institute Inc, 
Cary, NC), and R statistical software v.3.1 (http://www.r-project.org). 
 
RESULTS 
The study was carried out in a cohort of 290 HD patients, with mean age at recruitment of 74 
years (standard deviation 9.7). At recruitment, 134 patients (46.2%) were taking OAT (OAT-
yes). The median follow-up time was 4 years. During follow-up, 65/134 (48.5%) patients 
stopped taking warfarin, while 33/156 (21.1%) subjects without OAT at recruitment (OAT-
no) started to take it. During the 4-year follow-up there were 170 deaths (95 in OAT-no 
versus 75 in OAT-yes at recruitment; 25 and 22 per 100 patient years, respectively; P=0.4), 28 
thromboembolic events (17 in OAT-no versus 11 in OAT-yes at recruitment; 4.5 and 3.2 per 
100 patient years, respectively; P=0.4) and 95 haemorrhagic events (36 in OAT-no versus 59 
in OAT-yes at recruitment; 9.5 and 17 per 100 patient years, respectively; P=0.005). 
The main causes of death were: cachexia (n=49, 16.9%), sepsis (n=34, 11.7%), sudden death 
(n=18, 6.3%), cardiogenic shock and tumor (n=15, 5.2%). One patient died due to ischemic 
stroke and three for hemorrhagic stroke (0.6 and 1.0%, respectively). 
Table 1 shows the clinical characteristics of the OAT-no and OAT-yes patients at recruitment, 
before and after balancing for treatment propensity.   
A plain unadjusted Cox model did not show any difference between patients under OAT-no 
and OAT-yes at recruitment: HR=0.87 (95%CI: 0.64-1.18, P=0.37) for mortality, HR=0.60 
(95%CI: 0.26-1.36, P=0.22) for thromboembolic events and HR=1.57 (95%CI: 0.91-2.72, 
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P=0.11) for bleeding. Similar results were observed with  the ITT analysis of the IPTW cohort 
that did not show a difference regarding total mortality, cardiovascular mortality, 
thromboembolic and hemorrhagic events  (Table 2). The AT analysis, censoring patients 
when they switch treatment, showed that patients taking OAT at recruitment had a 
significantly lower mortality rate than those not taking it (HR 0.51, 95%CI 0.29-0.89, 
P=0.02), with a non-significant protective effect effect on cardiovascular mortality (HR 0.50, 
95%CI 0.22-1.16, P=0.1). A non-significant No benefit of OAT was evident on 
thromboembolic events, while a non-significant increase in bleedings was observed (HR 1.80, 
95%CI 0.91-3.58, P=0.09) (Table 2).  
The results from the sequential Cox regression model showed that among patients taking 
OAT at recruitment (n=134), those continuing OAT assumption (n=69) had a significant 
reduction in the risk of total (HR 0.28, 95%CI 0.14-0.53, P<0.001) and cardiovascular (HR 
0.21, 95%CI 0.11-0.40, P<0.001) mortality, compared to patients stopping the assumption 
during follow-up. There was a slight increase of mortality in patients with higher HASBLED 
score for cardiovascular mortality (HR 1.71, 95%CI 1.00-2.93, P=0.05). A higher TTR 
seemed to have a modest protective effect against thromboembolic events (HR 0.13, 95%CI 
0.013-1.37, P=0.09). Warfarin slightly increased the risk of bleeding .(HR 5.20, 95%CI 0.63-
42.70, P=0.12). In order to evaluate whether the beneficial effect of warfarin on mortality was 
due to the fact that patients who do not interrupt warfarin have a better INR, we stratified the 
analysis for TTR lower and higher than 60%: also in patients with a labile INR (TTR<60%) 
continuous warfarin intake had a beneficial effect. (HR 0.37, 95%CI 0.18-0.77, P=0.007). A 
more marked effect was seen in patients with TTR≥60% (HR 0.07, 95%CI 0.02-0.19 
P<0.001) (Table 3).The results were similar when patients who died within six months after 
warfarin withdrawal (n=15) were censored: OAT was still associated with a reduction of total 
(HR 0.44, 95%CI 0.23-0.84, P=0.013) and cardiovascular mortality (HR 0.36, 95%CI 0.19-
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0.66, P=0.001). Mortality results were confirmed also stratifying for TTR lower and higher 
than 60% (HR 0.49, 95%CI 0.24-0.99, P=0.048 and HR 0.24, 95%CI 0.07-0.82, P=0.023, 
respectively). 
At recruitment, 12 (4.1%) patients had a CHA2DS2-VASc score between 0-1, 149 (51.4%) 
between 2-4 and 129 (44.5%) between 5-9, while patients with a HASBLED score between 0-
1 were 3 (1%), between 2-3 were 137 (47.2%) and between 4-9 were 149 (51.4%). Total 
mortality was significantly related to both CHA2DS2-VASc (log-rank test P<0.001, Figure 
1A) and HASBLED score (log-rank test P=0.003, Figure 1B). Coherently we found higher 
rates of mortality with higher scores, when the scores were updated during follow-up: 8.4, 
18.4, 31.2 per 100 person years for CHA2DS2-VASc between 0-1, 2-4 and 5-9, respectively, 
and 0, 17.5, 26.8 per 100 patient years for HASBLED between 0-1, 2-3 and 4-9, respectively. 
Thromboembolic events (3.9 per 100 patient years) also increased with higher CHA2DS2-
VASc score during follow-up (0, 2.1 and 6.1 per 100 patient years for CHA2DS2-VASc 
between 0-1, 2-4 and 5-9, respectively) (Figure 2A), and similarly bleeding events (13.1 per 
100 patient years) increased with higher HASBLED score as updated during follow-up (0, 8.5 
and 15.6 per 100 patient years HASBLED between 0-1, 2-3 and 4-9, respectively) (Figure 
2B).  
 
DISCUSSION 
In HD patients with AF, during a follow-up of four years, warfarin assumption at recruitment 
was associated with a non-significant risk reduction in total mortality when an intention-to-
treat approach was taken, while the continued warfarin assumption was associated with a risk 
reduction in total mortality of about 50 percent with an as-treated approach. When subjects 
who continue to take OAT from recruitment onwards as compared to those who discontinue 
the treatment are considered, the benefit is also evident for cardiovascular mortality. Taking 
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warfarin was not associated with a significant decrease of thromboembolic events with both 
approaches, even if a trend towards a reduction of thromboembolism and an while there was a 
trend of increase ofd bleeding in patients receiving OAT was observed  with as-treated 
analysis.  The scores of thromboembolic and bleeding risk were effective in predicting both 
events and increased risk of mortality. 
Data on the relationship between OAT and risk of death in ESRD patients with AF are not 
conclusive. Two retrospective studies, evaluating the effect of warfarin on mortality without 
taking into account the reason for the prescription, showed reduced survival in subjects 
receiving OAT [14, 15]. More recently, evidence suggesting a protective effect of OAT on the 
risk of mortality emerged [4, 16]. To understand the relationship between warfarin and risk of 
death in HD patients with AF is a very complex problem for several reasons. The percentage 
of people taking OAT is often a minority compared to the number of patients who would have 
an indication in accordance with the current guidelines. In two recent studies, the prevalence 
of ESRD subjects with AF receiving warfarin was 8.4% [6] and 15% [17]. The 
underutilization of OAT in presence of ESRD makes it difficult to compare its effect in HD 
population versus patients with AF, but with preserved renal function. Moreover, a high 
percentage of HD patients taking OAT suspend it after severe bleeding [6, 7]. For these 
reasons the results of intention-to-treat analysis are difficult to interpret. To overcome the 
problem, Shen JI, in a cohort of HD patients from a registry of newly diagnosed AF, 
performed an as-treated analysis, after applying a propensity score approach to treatment. The 
author’s conclusion was that patients under OAT had a better survival than those who were 
not anticoagulated [6]. Applying a similar statistical approach, our study, which has the 
advantage of being a prospective study where the INR values and the exact date of OAT 
suspension are known, comes to similar conclusions. Moreover the Cox model evaluating the 
effect of stopping OAT during follow-up reveals that a drug withdrawal in patients taking 
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OAT at recruitment is accompanied by an increase in mortality from both all and 
cardiovascular causes. Our preliminary results had suggested the presence of a slight non 
significant trend towards a better survival in HD patients with AF taking warfarin, compared 
with those not anticoagulated [7]. The present study indicates that, in order that the protective 
effect of the drug becomes evident, it is necessary that only the actual time of warfarin 
assumption is considered. Although patients who benefit most from taking warfarin are those 
who have a higher TTR, the survival of patients with labile INR is still better than that of 
those who suspend the drug. 
In our population, OAT warfarin appears to have a modest protective effect does not seem to 
protect against the risk of stroke. This finding is in line with recent retrospective studies based 
on registry data [2, 17, 18], while only a large Danish study described a clear reduction in the 
risk of stroke associated with taking warfarin [3]. In the latter study, however, peritoneal 
dialysis patients and transplant patients are lumped into a group called "renal replacement", 
and this makes it difficult to compare the results with those of other studies.In most of  None 
of these studies it is not taken into account took into account that many patients probably 
discontinued treatment during follow-up and this weakens their conclusions. Also in the only 
study in which an as-treated analysis was performed [6], warfarin did not emerge as a 
protective factor of thromboembolic events. In all of these studies however Moreover, 
patients taking OAT at recruitment were a minority compared to those who did not take it 
(from 6% to 25%), except for the Canadian study (46% of OAT patients) [2]. A recent study 
[17] shows that ESRD patients with AF have, as previously highlighted [19], an increased risk 
of total and cardiovascular mortality, but not an increased risk of stroke. Authors suggest that 
the net clinical benefit of stroke prevention for patients on dialysis with AF has to be 
rethought. In our cohort the rate of thromboembolic events was relatively low (3.9 per 100 
patient years) compared to what expected, given the elevated CHA2DS2-VASc scores. A 
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similar relatively low rate of stroke was described before in ESRD patients with AF by others 
authors [20]. Despite ESRD is associated with an increased of overall stroke  (i.e. 
thromboembolic and thrombotic cerebrovascular events) [21], in HD patients with AF  the 
incidence of thromboembolic stroke could be lower than expected because of a protective 
effect of possible platelets disorders present in uremia [22] and the chronic administration, 
three times a week, of heparin during each HD session. Therefore, we cannot exclude that the 
protective effect of warfarin against thromboembolic risk can be blunted by the fact that HD 
patients are already partially anticoagulated. Oral aAnticoagulation has been shown to protect 
against myocardial infarction and to be safe and effective in coronary artery disease patients 
with and without concomitant AF [21, 242]. Moreover a recent study demonstrated in older 
adults with AF a benefit from OAT in terms of lower mortality, regardless of poor health and 
functional condition [2534].  It’s possible that, also in HD patients, OAT might have a 
positive effect in HD patients not only necessarily through a reduction of thromboembolic 
risk. Despite ESRD is associated with an increased of overall stroke  (i.e. thromboembolic 
and thrombotic cerebrovascular events) [243], in HD patients with AF  the incidence of 
thromboembolic stroke could be lower than expected because of a protective effect of 
possible platelets disorders present in uremia [254] and the chronic administration, three times 
a week, of heparin during each HD session. At the same time, these two factors may be 
responsible for a higher risk of bleeding. The rate of bleeding events of our population was 
extremely high (13.1 per 100 patient years) and significantly exceeded that of 
thromboembolic events. The haemorrhagic risk tends to increase in patients taking OAT, 
according to what has already been reported in the literature [2, 8] and stresses the importance 
of a careful assessment of the bleeding risk when deciding whether to start OAT in an ESRD 
patient. In HD patients with AF and particularly high haemorrhagic risk, alternatives to OAT 
as percutaneous closure occlusion of the left atrial appendage may be considered [265].  
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In our population, both CHA2DS2-VASc and HASBLED values were very high and both 
scores were associated with an increase of total mortality and thromboembolic and 
haemorrhagic events, respectively. Also if the two scores were developed in populations 
which excluded ESRD subjects, this result confirms that they have some utility in identifying 
frail patients who need particular attention in warfarin prescription also among HD patients, 
even if the small percentage of subjects with low scores, may reduce the possibility to 
stratified appropriately patients at lower thromboembolic and bleeding risk.  
Our study has some limitations and strengths. We cannot be sure that all AF episodes have 
been included in our study, especially for paroxysmal forms that are often unrecognized. 
However we decided to include only cases with a clear electrocardiographic documentation to 
be sure of the real presence of the arrhythmia. By note, the prevalence of AF in our population 
was similar to that reported in the literature [27].Our study, compared to the majority of those 
available, has the advantage of being prospective and of considering many factors that are 
useful in guiding clinical practice. However, it has the limitation of not being a randomized 
trial, even if we carefully considered in our analysis all statistical corrections that allow to limit 
the bias due to lack of randomization. In our opinion, however, a randomized study has a low 
feasibility in this context. Our patients often have high haemorrhagic scores and the risk of 
experiencing bleeding increases with increasing HASBLED. Warfarin is associated with the 
possibility of suffering bleeding episodes during follow-up. We would be reluctant to 
randomize a patient with very high HASBLED to take OAT and even if we did, there would 
be a high chance for this patient to drop out for bleeding. In addition, our data suggest a 
protective effect of warfarin in terms of mortality, so we would possibly deprive a HD patient 
able to take OAT of the opportunity to do so. We acknowledge that the intention-to-treat 
analysis is hampered by treatment crossover, while as-treated analysis might be subject to 
selection bias due to adverse events occurring in the follow-up, causing warfarin withdrawal. 
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Those patients who succeeded in continuing to take the therapy could be the ones who were 
less frail and had a better compliance. However, to assess this assumption, we performed a 
sensitivity analysis in which we censored patients who died within six months of warfarin 
withdrawal and we obtained similar results. 
In conclusion, our data suggest that in a HD population presenting both a high 
thromboembolic and bleeding risk, a protective effect of warfarin on total and cardiovascular 
mortality is present in patients taking OAT without discontinuations and with INR kept within 
the therapeutic range, with a slight decrease of thromboembolic events. 
. The study also shows that CHA2DS2-VASc and HASBLED scores can be useful also in HD 
patients to identify those at highest risk of mortality and thromboembolic and bleeding events. 
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TABLES HEADINGS 
Table 1: Patient characteristics by OAT at recruitment before and after balancing for 
treatment propensity 
Table 2: Results from intention-to-treat (ITT) and as-treated (AS) Cox regression model on 
warfarin administration (Yes vs No) effect 
Table 3: Sequential Cox regression model on mortality, cardiovascular mortality, bleeding 
and thromboembolic events in cohort of patients who always took OAT (n=69) vs those who 
took OAT at recruitment, but suspended it during follow-up (n=65) 
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LEGENDS TO FIGURES 
 
Figure 1: Kaplan-Meier mortality curves by A) CHA2DS2-VASCS and B) HASBLED scores 
 
Figure 2: A) Thromboembolic event rate by CHA2DS2-VASCS and B) Bleeding event rate by 
HASBLED score 
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Effect of oral anticoagulant therapy on mortality in end stage renal disease patients with 
atrial fibrillation: a prospective study 
 
 
ABSTRACT 
Background: Aim of this study was to evaluate, in a cohort of haemodialysis patients with 
atrial fibrillation (AF), the relationship between oral anticoagulant therapy (OAT) and 
mortality, thromboembolic and haemorrhagic risk. 
Methods: 290 patients with AF were prospectively followed-up for four years. Warfarin and 
antiplatelet intake, age, dialytic age, comorbidities, CHA2DS2-VASc and HASBLED scores 
were considered as predictors of hazard of death, thromboembolic and bleeding events. In 
patients taking OAT, the International Normalized Ratio (INR) was assessed and the 
percentage time in the Target Therapeutic Range (TTR) was calculated. 
Results: At recruitment, 134/290 patients were taking warfarin. During follow-up there were 
170 deaths, 28 thromboembolic events and 95 bleedings. After balancing for treatment 
propensity, intention-to-treat analysis on OAT assumption at recruitment did not show 
differences in total mortality, thromboembolic events and bleedings. As-treated analysis, 
accounting for treatment switch, showed that patients taking OAT at recruitment had a 
significantly lower mortality than those not taking it (HR 0.53, 95%CI 0.28-0.90, P=0.04), 
with a slight benefit of OAT  on thromboembolic events (HR 0.36, 95%CI 0.13-1.05, 
P=0.06), and a non-significant increase in bleedings. Among patients taking OAT at 
recruitment, those continuing warfarin assumption had a significant reduction in the risk of 
total (HR 0.28, 95%CI 0.14-0.53, P<0.001) and cardiovascular (HR 0.21, 95%CI 0.11-0.40, 
P<0.001) mortality, compared to patients stopping assumption.  
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Conclusions: In haemodialysis patients with AF, continuously taking warfarin is associated 
with a reduction of the risk of total and cardiovascular mortality, and with a slight decrease of 
thromboembolic events. 
 
 
KEYWORDS: warfarin, haemodialysis, atrial fibrillation, mortality, stroke, bleeding  
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INTRODUCTION 
Data on the risk/benefit ratio of warfarin in patients with atrial fibrillation (AF) and end stage 
renal disease (ESRD) continue to be inconclusive, despite the high prevalence of the 
arrhythmia in this population. Some authors report an increased risk of complications derived 
from the use of oral anticoagulant therapy (OAT) in haemodialysis (HD) patients with AF, 
without any benefit in terms of thromboembolic risk protection [1, 2]. Other studies are less 
negative [3, 4] but a big uncertainty remains on how to approach these patients [5]. One major 
problem is the lack of prospective and randomized data. In fact almost all published studies 
are based on retrospective analyses of registry data. Recently a large retrospective study 
showed that warfarin was associated with a reduced mortality in a cohort of HD patients with 
newly diagnosed AF [6]. This study accounted for confounding by indication with propensity 
score, but being a register study not all potential confounders were available, in particular 
International Normalized Ratio (INR) was missing and OAT assumption was based on the 
prescription. We set a prospective study in a population of HD patients with AF, where 
information on the exact time of the possible withdrawal of warfarin and on the INR values in 
subjects taking OAT were collected, over the baseline characteristics of patients. Preliminary 
results on two years of follow-up indicated that warfarin significantly increased the incidence 
of bleeding without reducing thromboembolic events. Furthermore, the study suggested the 
presence of a trend towards a better survival in patients receiving OAT [7]. However, those 
early results needed to be completed with a long-term efficacy and safety evaluation of 
warfarin assumption. 
The main purpose of the present study was to evaluate prospectively, in a cohort of patients 
with ESRD and AF followed-up for four years, the relationship between OAT and mortality, 
thromboembolic and haemorrhagic risk .We evaluated long-term efficacy and safety of OAT 
using a causal method approach to limit the confounding by indication and to account for the 
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updated value of confounders/variables over the follow-up. Secondary aim was to test the 
predictive value of the CHA2DS2-VASc and HASBLED scores on mortality, thromboembolic 
and haemorrhagic events, given that these scores are indicated by the Cardiology Guidelines 
to identify patients at increased thromboembolic and haemorrhagic risk [8], but were 
developed in cohorts of patients in which HD was an exclusion criterion.  
 
SUBJECTS AND METHODS 
All patients alive and under observation in 10 Italian dialysis centers on 31/10/2010 were 
considered (n=1529) and their clinical charts revised for eligibility to the study. Peritoneal 
dialysis patients were not included. All subjects with at least one documented paroxysmal 
(self-terminating) or persistent (required termination by pharmacological or electrical 
cardioversion) AF episode, or with permanent AF (when there has been a joint decision by the 
patient and clinician to cease further attempts to restore and/or maintain sinus rhythm) were 
recruited, for a total of 290 patients (see Supplementary figure 1).  
At recruitment  data were collected on the presence of hypertension (systolic blood pressure 
≥140mmHg and/or diastolic blood pressure ≥90mmHg before the beginning of the HD 
session or anti-hypertensive drugs administration), diabetes mellitus, peripheral artery disease 
(clinical presence of claudication and/or evidence of significant stenosis of main arterial 
trunks by doppler examination), ischemic heart disease (previous myocardial infarction or 
coronary revascularization procedures and/or previous hospitalization due to acute coronary 
syndrome), heart failure (presence of left-ventricular dysfunction- left-ventricular ejection 
fraction<50%- and/or previous hospitalization due to acute or chronic heart failure), previous 
strokes (ischemic or haemorrhagic defined by computed tomographic scan or nuclear 
magnetic resonance), and major bleeding episodes (haemorrhagic episode requiring 
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hospitalization or blood transfusion, or causing a haemoglobin plasma level reduction > 2g/dl) 
and on administration of antiplatelets and anticoagulants [7]. 
Cardiac ultrasound examination was performed in all the patients during the mid-week 
dialysis interval. Collected echocardiography data were: left ventricular ejection fraction 
(LVEF, %) and the presence of left ventricular hypertrophy (LVH), which was defined as left-
ventricular mass normalized for body surface area >125 g/m2 according to the Penn-cube 
formula, or when its presence was described in the report. 
Patients were prospectively followed-up for four years (until 31/10/2014 or death) and their 
clinical charts were updated at each dialysis session. The new onset of permanent AF, stroke, 
bleeding, cardiovascular events (ischemic and heart failure episodes that required 
hospitalization), and antiplatelet and anticoagulant treatment modifications were recorded. 
In patients taking OAT, the INR values were assessed at least once a month and the 
percentage time in the target INR range (Target Therapeutic Range, TTR) was calculated [9]. 
Only one center referred patients to a Thrombosis Clinic, while in the others the nephrologist 
took care of warfarin dosage (the policy was to keep INR between 2 and 3). 
Thromboembolic and haemorrhagic risk was calculated using the CHA2DS2-VASc and 
HASBLED score, respectively [8].  
Procedures were performed according to the Helsinki declaration for ethical treatment of 
human subjects and approved by the local ethical committee. Informed consent was obtained 
from the enrolled subjects. 
Statistical methods 
All data were centrally revised. Patients were considered under OAT at recruitment if taking 
OAT at 31/10/2010. Rates of mortality, thromboembolic and haemorrhagic events were 
computed for patients on and not on OAT at recruitment and compared by the Poisson model.  
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Marginal structural models  
In order to evaluate the effect of OAT on mortality, thromboembolic and haemorrhagic risk, 
we created a pseudo-population (that mimics a randomized trial) which mitigates the selection 
bias in OAT treatment assignment at recruitment [10]. This pseudo-population, created by the 
use of (stabilized) Inverse Probability of Treatment (and censoring) Weights (IPTW), is called 
the “IPTW cohort”. IPTW were computed by a multivariable logistic model on the propensity 
to be under OAT at recruitment that included age, diabetes mellitus, ischemic and 
bleeding/haemorrhagic strokes, ischemic heart disease, CHA2DS2-VASc and HASBLED 
score, type of AF, left ventricular ejection fraction <50% and left ventricular hypertrophy 
(and their first degree interactions), gender, dialytic age, hypertension, heart failure, 
peripheral artery disease and antiplatelet therapy. In order to evaluate the balance induced by 
these weights, the confounders among patients under OAT and not in this pseudo-population 
were compared by standardized differences [11]. Furthermore, an inverse probability of 
censoring weight was also applied to account for loss to follow-up and informative censoring 
due to death when analysing thromboembolic and haemorrhagic outcomes. Final weights 
were computed as the product of the stabilized weights [10] for treatment and censoring 
(trimming was not necessary as weights ranged between 0.5 to 9.5). 
The weighted Cox regression model with robust standard error was applied to the IPTW 
cohort to assess the effect of OAT administration at recruitment on different relevant 
endpoints. The model was adjusted for each covariate which after balancing (IPTW cohort) 
still showed a standardized difference greater than 10% between the two groups (i. e. 
bleeding/haemorrhagic stroke and permanent AF). Results of the Cox models are expressed in 
terms of estimated hazard ratios (HR), 95% confidence intervals (95%CI) and P-values. 
In analogy to a randomized trial, two analyses were performed: intention-to-treat (ITT) and 
as-treated (AT) analyses. In the first one, the treatment (OAT) classification at recruitment 
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was retained for the whole follow-up, while in the AT analysis patients who switched 
treatment were artificially censored (this artificial censoring was also considered in the 
inverse probability of censoring weights). 
Sequential Cox 
In order to better evaluate the effect of the time dependent variables, including OAT 
assumption, on the risk of mortality, thromboembolic and haemorrhagic events, we evaluated 
the effect of stopping OAT by the sequential Cox approach [12]. This method mimics several 
randomized controlled trials, based on individuals stopping OAT in time intervals (of one 
month), and obtains an overall treatment effect estimate. We adjusted for gender and the 
updated values (at the beginning of each month) of age, percentage of TTR ,CHA2DS2-VASc 
and HASBLED scores, presence of permanent AF and use of antiplatelets. 
The effect of suspending OAT was also estimated stratifying according to TTR > or <60% 
[13]. As it was possible that some patients had discontinued therapy because in terminal 
conditions, a sensitivity analysis was performed, in which we censored patients died within 
six months of warfarin withdrawal.  
 
Score analysis 
The Kaplan-Meier estimator was used to describe survival in subgroups defined according to 
CHA2DS2-VASc and HASBLED scores at recruitment. We also computed rates of mortality, 
thromboembolic and haemorrhagic events by the updated value of the scores during follow-
up. 
Analyses were carried out by means of the statistical software SAS v.9.4 (SAS Institute Inc, 
Cary, NC), and R statistical software v.3.1 (http://www.r-project.org). 
 
RESULTS 
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The study was carried out in a cohort of 290 HD patients, with mean age at recruitment of 74 
years (standard deviation 9.7). At recruitment, 134 patients (46.2%) were taking OAT (OAT-
yes). The median follow-up time was 4 years. During follow-up, 65/134 (48.5%) patients 
stopped taking warfarin, while 33/156 (21.1%) subjects without OAT at recruitment (OAT-
no) started to take it. During the 4-year follow-up there were 170 deaths (95 in OAT-no 
versus 75 in OAT-yes at recruitment; 25 and 22 per 100 patient years, respectively; P=0.4), 28 
thromboembolic events (17 in OAT-no versus 11 in OAT-yes at recruitment; 4.5 and 3.2 per 
100 patient years, respectively; P=0.4) and 95 haemorrhagic events (36 in OAT-no versus 59 
in OAT-yes at recruitment; 9.5 and 17 per 100 patient years, respectively; P=0.005). 
The main causes of death were: cachexia (n=49, 16.9%), sepsis (n=34, 11.7%), sudden death 
(n=18, 6.3%), cardiogenic shock and tumor (n=15, 5.2%). One patient died due to ischemic 
stroke and three for hemorrhagic stroke (0.6 and 1.0%, respectively). 
Table 1 shows the clinical characteristics of the OAT-no and OAT-yes patients at recruitment, 
before and after balancing for treatment propensity.   
A plain unadjusted Cox model did not show any difference between patients under OAT-no 
and OAT-yes at recruitment: HR=0.87 (95%CI: 0.64-1.18, P=0.37) for mortality, HR=0.60 
(95%CI: 0.26-1.36, P=0.22) for thromboembolic events and HR=1.57 (95%CI: 0.91-2.72, 
P=0.11) for bleeding. Similar results were observed with the ITT analysis of the IPTW cohort 
that did not show a difference regarding total mortality, cardiovascular mortality, 
thromboembolic and hemorrhagic events (Table 2). The AT analysis, censoring patients when 
they switch treatment, showed that patients taking OAT at recruitment had a significantly 
lower mortality rate than those not taking it, with a non-significant protective effect on 
thromboembolic events, while a non-significant increase in bleedings was observed (Table 2).  
The results from the sequential Cox regression model showed that among patients taking 
OAT at recruitment (n=134), those continuing OAT assumption (n=69) had a significant 
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reduction in the risk of total and cardiovascular mortality, compared to patients stopping the 
assumption during follow-up. Warfarin slightly increased the risk of bleeding. In order to 
evaluate whether the beneficial effect of warfarin on mortality was due to the fact that patients 
who do not interrupt warfarin have a better INR, we stratified the analysis for TTR lower and 
higher than 60%: also in patients with a labile INR (TTR<60%) continuous warfarin intake 
had a beneficial effect. A more marked effect was seen in patients with TTR≥60% (Table 
3).The results were similar when patients who died within six months after warfarin 
withdrawal (n=15) were censored: OAT was still associated with a reduction of total (HR 
0.44, 95%CI 0.23-0.84, P=0.013) and cardiovascular mortality (HR 0.36, 95%CI 0.19-0.66, 
P=0.001). Mortality results were confirmed also stratifying for TTR lower and higher than 
60% (HR 0.49, 95%CI 0.24-0.99, P=0.048 and HR 0.24, 95%CI 0.07-0.82, P=0.023, 
respectively). 
At recruitment, 12 (4.1%) patients had a CHA2DS2-VASc score between 0-1, 149 (51.4%) 
between 2-4 and 129 (44.5%) between 5-9, while patients with a HASBLED score between 0-
1 were 3 (1%), between 2-3 were 137 (47.2%) and between 4-9 were 149 (51.4%). Total 
mortality was significantly related to both CHA2DS2-VASc (log-rank test P<0.001, Figure 
1A) and HASBLED score (log-rank test P=0.003, Figure 1B). Coherently we found higher 
rates of mortality with higher scores, when the scores were updated during follow-up: 8.4, 
18.4, 31.2 per 100 person years for CHA2DS2-VASc between 0-1, 2-4 and 5-9, respectively, 
and 0, 17.5, 26.8 per 100 patient years for HASBLED between 0-1, 2-3 and 4-9, respectively. 
Thromboembolic events (3.9 per 100 patient years) also increased with higher CHA2DS2-
VASc score during follow-up (0, 2.1 and 6.1 per 100 patient years for CHA2DS2-VASc 
between 0-1, 2-4 and 5-9, respectively) (Figure 2A), and similarly bleeding events (13.1 per 
100 patient years) increased with higher HASBLED score as updated during follow-up (0, 8.5 
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and 15.6 per 100 patient years HASBLED between 0-1, 2-3 and 4-9, respectively) (Figure 
2B).  
 
DISCUSSION 
In HD patients with AF, during a follow-up of four years, warfarin assumption at recruitment 
was associated with a non-significant risk reduction in total mortality when an intention-to-
treat approach was taken, while the continued warfarin assumption was associated with a risk 
reduction in total mortality of about 50 percent with an as-treated approach. When subjects 
who continue to take OAT from recruitment onwards as compared to those who discontinue 
the treatment are considered, the benefit is also evident for cardiovascular mortality. Taking 
warfarin was not associated with a significant decrease of thromboembolic events with both 
approaches, even if a trend towards a reduction of thromboembolism and an increase of 
bleeding in patients receiving OAT was observed with as-treated analysis. The scores of 
thromboembolic and bleeding risk were effective in predicting both events and increased risk 
of mortality. 
Data on the relationship between OAT and risk of death in ESRD patients with AF are not 
conclusive. Two retrospective studies, evaluating the effect of warfarin on mortality without 
taking into account the reason for the prescription, showed reduced survival in subjects 
receiving OAT [14, 15]. More recently, evidence suggesting a protective effect of OAT on the 
risk of mortality emerged [4, 16]. To understand the relationship between warfarin and risk of 
death in HD patients with AF is a very complex problem for several reasons. The percentage 
of people taking OAT is often a minority compared to the number of patients who would have 
an indication in accordance with the current guidelines. In two recent studies, the prevalence 
of ESRD subjects with AF receiving warfarin was 8.4% [6] and 15% [17]. The 
underutilization of OAT in presence of ESRD makes it difficult to compare its effect in HD 
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population versus patients with AF, but with preserved renal function. Moreover, a high 
percentage of HD patients taking OAT suspend it after severe bleeding [6, 7]. For these 
reasons the results of intention-to-treat analysis are difficult to interpret. To overcome the 
problem, Shen JI, in a cohort of HD patients from a registry of newly diagnosed AF, 
performed an as-treated analysis, after applying a propensity score approach to treatment. The 
author’s conclusion was that patients under OAT had a better survival than those who were 
not anticoagulated [6]. Applying a similar statistical approach, our study, which has the 
advantage of being a prospective study where the INR values and the exact date of OAT 
suspension are known, comes to similar conclusions. Moreover the Cox model evaluating the 
effect of stopping OAT during follow-up reveals that a drug withdrawal in patients taking 
OAT at recruitment is accompanied by an increase in mortality from both all and 
cardiovascular causes. Our preliminary results had suggested the presence of a slight non-
significant trend towards a better survival in HD patients with AF taking warfarin, compared 
with those not anticoagulated [7]. The present study indicates that, in order that the protective 
effect of the drug becomes evident, it is necessary that only the actual time of warfarin 
assumption is considered. Although patients who benefit most from taking warfarin are those 
who have a higher TTR, the survival of patients with labile INR is still better than that of 
those who suspend the drug. 
In our population, OAT warfarin appears to have a modest protective effect against the risk of 
stroke. This finding is in line with recent retrospective studies based on registry data [2, 17, 
18], while only a large Danish study described a clear reduction in the risk of stroke 
associated with taking warfarin [3]. In the latter study, however, peritoneal dialysis patients 
and transplant patients are lumped into a group called "renal replacement", and this makes it 
difficult to compare the results with those of other studies. In most  of these studies it is not 
taken into account that many patients probably discontinued treatment during follow-up and 
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this weakens their conclusions Moreover, patients taking OAT at recruitment were a minority 
compared to those who did not take it (from 6% to 25%), except for the Canadian study (46% 
of OAT patients) [2]. A recent study [17] shows that ESRD patients with AF have, as 
previously highlighted [19], an increased risk of total and cardiovascular mortality, but not an 
increased risk of stroke. Authors suggest that the net clinical benefit of stroke prevention for 
patients on dialysis with AF has to be rethought. In our cohort the rate of thromboembolic 
events was relatively low (3.9 per 100 patient years) compared to what expected, given the 
elevated CHA2DS2-VASc scores. A similar relatively low rate of stroke was described before 
in ESRD patients with AF by others authors [20]. Despite ESRD is associated with an 
increase of overall stroke  (i.e. thromboembolic and thrombotic cerebrovascular events) [21], 
in HD patients with AF  the incidence of thromboembolic stroke could be lower than 
expected because of a protective effect of possible platelets disorders present in uremia [22] 
and the chronic administration, three times a week, of heparin during each HD session. 
Therefore, we cannot exclude that the protective effect of warfarin against thromboembolic 
risk can be blunted by the fact that HD patients are already partially anticoagulated. Oral 
anticoagulation has been shown to protect against myocardial infarction and to be safe and 
effective in coronary artery disease patients with and without concomitant AF [2, 24]. 
Moreover a recent study demonstrated in older adults with AF a benefit from OAT in terms of 
lower mortality, regardless of poor health and functional condition [25].  It’s possible that, 
also in HD patients, OAT might have a positive effect not only through a reduction of 
thromboembolic risk. The rate of bleeding events of our population was extremely high (13.1 
per 100 patient years) and significantly exceeded that of thromboembolic events. The 
haemorrhagic risk tends to increase in patients taking OAT, according to what has already 
been reported in the literature [2, 8] and stresses the importance of a careful assessment of the 
bleeding risk when deciding whether to start OAT in an ESRD patient. In HD patients with 
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AF and particularly high haemorrhagic risk, alternatives to OAT as percutaneous occlusion of 
the left atrial appendage may be considered [26].  
In our population, both CHA2DS2-VASc and HASBLED values were very high and both 
scores were associated with an increase of total mortality and thromboembolic and 
haemorrhagic events, respectively. Also if the two scores were developed in populations 
which excluded ESRD subjects, this result confirms that they have some utility in identifying 
frail patients who need particular attention in warfarin prescription also among HD patients, 
even if the small percentage of subjects with low scores, may reduce the possibility to 
stratified appropriately patients at lower thromboembolic and bleeding risk.  
Our study has some limitations and strengths. We cannot be sure that all AF episodes have 
been included in our study, especially for paroxysmal forms that are often unrecognized. 
However we decided to include only cases with a clear electrocardiographic documentation to 
be sure of the real presence of the arrhythmia. By note, the prevalence of AF in our population 
was similar to that reported in the literature [27].Our study, compared to the majority of those 
available, has the advantage of being prospective and of considering many factors that are 
useful in guiding clinical practice. However, it has the limitation of not being a randomized 
trial, even if we carefully considered in our analysis all statistical corrections that allow to limit 
the bias due to lack of randomization. In our opinion, however, a randomized study has a low 
feasibility in this context. Our patients often have high haemorrhagic scores and the risk of 
experiencing bleeding increases with increasing HASBLED. Warfarin is associated with the 
possibility of suffering bleeding episodes during follow-up. We would be reluctant to 
randomize a patient with very high HASBLED to take OAT and even if we did, there would 
be a high chance for this patient to drop out for bleeding. In addition, our data suggest a 
protective effect of warfarin in terms of mortality, so we would possibly deprive a HD patient 
able to take OAT of the opportunity to do so. We acknowledge that the intention-to-treat 
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analysis is hampered by treatment crossover, while as-treated analysis might be subject to 
selection bias due to adverse events occurring in the follow-up, causing warfarin withdrawal. 
Those patients who succeeded in continuing to take the therapy could be the ones who were 
less frail and had a better compliance. However, to assess this assumption, we performed a 
sensitivity analysis in which we censored patients who died within six months of warfarin 
withdrawal and we obtained similar results. 
In conclusion, our data suggest that in a HD population presenting both a high 
thromboembolic and bleeding risk, a protective effect of warfarin on total and cardiovascular 
mortality is present in patients taking OAT without discontinuations and with INR kept within 
the therapeutic range, with a slight decrease of thromboembolic events. 
The study also shows that CHA2DS2-VASc and HASBLED scores can be useful also in HD 
patients to identify those at highest risk of mortality and thromboembolic and bleeding events. 
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TABLES HEADINGS 
Table 1: Patient characteristics by OAT at recruitment before and after balancing for 
treatment propensity 
Table 2: Results from intention-to-treat (ITT) and as-treated (AS) Cox regression model on 
warfarin administration (Yes vs No) effect 
Table 3: Sequential Cox regression model on mortality, cardiovascular mortality, bleeding 
and thromboembolic events in cohort of patients who always took OAT (n=69) vs those who 
took OAT at recruitment, but suspended it during follow-up (n=65) 
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Table 1  
 FULL COHORT IPTW COHORT 
 OAT ITT 
Standardized 
difference 
OAT ITT 
Standardized 
difference 
 NO YES NO YES 
 
 N % N % N % N % 
Total 156  134   149.9160.3  134.0130.0   
Male gender 88 56.4 86 64.2 15.9%16% 88.194.3 58.858.8 84.684.7 63.165.2 8.8%1% 
Age    ≥75 years 86 55.1 69 51.5 -7.3%-7% 77.076.8 51.447.9 72.770.3 54.254.1 5.7%1% 
          median (1st - 3rd quartile) 76(67-82) 76(68-80)  75(64-82) 76(68-80) 76(64-82) 
Dialytic age ≥3 years 92 59.0 80 59.7 1.5%1% 89.192.8 59.557.9 78.375.4 58.558.0 -2.1%0% 
         median (1st - 3rd quartile) 
4.3(1.8-
8.3) 
3.7(1.6-
7.2) 
 4.4(1.4-9.5) 3.6(1.5-10.0)  
Charlson Comorbidity 
Index 
         median (1st - 3rd quartile) 
3(1-6) 3(2-5)  3(2-6)   
Presence of:           
Formatted Table
Table 1 marked and clean Click here to download Table Table 1 to sumbit-1.docx 
Hypertension 133 85.3 102 76.1 -23.3%23% 121.2126.1 80.878.7 110.9105.9 82.881.5 5.0%-1% 
Diabetes mellitus 52 33.3 39 29.1 -9.1%9% 49.355.8 32.934.8 38.442.0 28.732.3 -9.2%0% 
Heart failure 57 36.5 58 43.3 13.8%-14% 60.067.7 40.042.2 59.753.0 44.540.8 9.1%0% 
Ischaemic stroke 22 14.1 21 15.7 4.4%-4% 24.327.9 16.217.4 20.921.2 15.616.3 -1.7%0% 
Bleeding/Haemorrhagic 
stroke 
41 26.3 16 11.9 -37.1%37% 
30.530.0 20.418.7 20.824.9 15.519.2 -12.7%0% 
Permanent AF 33 21.2 68 50.7 64.8%-65% 49.356.0 32.934.9 51.845.4 38.734.9 12.0%0% 
    Ischaemic heart disease 79 50.6 61 45.5 -10.3%-10.3% 73.6 49.1 67.5 50.4 2.5% 
    Peripheral artery 
disease 
106 67.9 95 70.9 
6.4% 
103.9 69.3 93.2 69.6 0.6% 
    LVEF <=50% 40 25.6 33 24.6 -2.3% 43.8 29.2 35.1 26.2 -6.8% 
    LVH 85 54.5 80 59.7 10.6% 85.0 56.7 81.5 60.8 8.2% 
Administration of 
Antiplatelet therapy 
107 68.6 32 23.9 
-100.3% 
100% 
76.575.2 51.146.9 69.362.3 51.747.9 1.3%0% 
CHA2DS2-VASCS           
0-1 9 5.8 3 2.2 -18.1%-18% 6.35.8 4.23.6 3.53.2 2.62.5 -8.7%-1% 
2-4 72 46.1 77 57.5 22.8%23% 79.285.4 52.853.3 72.474.0 54.056.9 2.4%0% 
Formatted Table
5-9 75 48.1 54 40.3 -15.7%-16% 64.369.1 42.943.1 58.152.8 43.340.6 0.8%0% 
HASBLED*           
0-1 1 0.6 3 2.2 13.4%1% 1.72.8 1.11.7 1.91.8 1.41.4 2.2%0% 
2-3 43 27.6 94 70.2 94.2%6% 68.366.6 45.641.6 61.174.9 45.657.6 0.0%2% 
4-9 112 71.8 37 27.6 -98.5%-6% 79.990.9 53.356.7 71.153.3 53.141.0 -0.5%-2% 
*It does not include the score related to labile INR, because unavailable at recruitment. 
Note: IPTW COHORT: Inverse Probability of Treatment Weights cohort 
AF: atrial fibrillation; LVEF: left ventricular ejection fraction, LVH: left ventricular hypertrophy 
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Table 2 
 
OUTCOME ANALYSIS N. events HR 95%CI P-value 
MORTALITY 
ITT 170 0.910.82 
0.56; 1.480.54; 
1.23 
0.70.3 
AT 115 0.530.51 
0.28; 0.90.29; 
0.89 
0.040.02 
CARDIOVASCULAR MORTALITY 
ITT 43 1.151.04 
0.47; 2.800.51; 
2.13 
0.80.9 
AT 31 0.490.50 
0.14; 1.660.22; 
1.16 
0.30.1 
THROMBOEMBOLIC EVENT 
ITT 25 0.440.84 
0.16; 1.200.32; 
2.17 
0.10.7 
AT 24 0.360.71 
0.13; 1.050.28; 
1.95 
0.060.5 
BLEEDING EVENT 
ITT 55 1.161.33 
0.48; 2.820.70; 
2.66 
0.70.4 
AT 49 1.791.80 
0.72; 4.390.91; 
3.58 
0.20.09 
Note: only first event was evaluate 
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OUTCOME ANALYSIS N. events HR 95%CI P-value 
MORTALITY 
ITT 170 0.91 0.56; 1.48 0.7 
AT 115 0.53 0.28; 0.90 0.04 
CARDIOVASCULAR MORTALITY 
ITT 43 1.15 0.47; 2.80 0.8 
AT 31 0.49 0.14; 1.66 0.3 
THROMBOEMBOLIC EVENT 
ITT 25 0.44 0.16; 1.20 0.1 
AT 24 0.36 0.13; 1.05 0.06 
BLEEDING EVENT 
ITT 55 1.16 0.48; 2.82 0.7 
AT 49 1.79 0.72; 4.39 0.2 
Note: only first event was evaluate
 
Table 3 
 OAT (Yes vs No) 
 HR 95%CI P-value 
MORTALITY* 0.28 0.14; 0.53 <0.001 
Patients with TTR ≥60%** 0.07 0.02;0.19 <0.001 
Patients with TTR<60%** 0.37 0.18; 0.77 0.007 
CARDIOVASCULAR MORTALITY* 0.21 0.11; 0.40 <0.001 
THROMBOEMBOLIC EVENTS* 4.41 0.28; 69.02 0.290 
BLEEDING EVENTS* 5.20 0.63; 42.70 0.125 
Note: TTR: Percentage time in target INR range 
*Model adjusted for gender, age (years), TTR, CHA2DS2-VASCS, HASBLED, antiplatelet therapy 
and permanent atrial fibrillation 
**Model adjusted for gender, age (years), CHA2DS2-VASCS, HASBLED, antiplatelet therapy and 
permanent atrial fibrillation 
Table 3 Click here to download Table Revised Table 3 clean copy.docx 
Figure 1 Click here to download Figure Revised Figure 1 clean copy.tif 
Figure 2 Click here to download Figure Revised Figure 2 clean copy.tif 
Figure S1: Patient selection flow-chart. 
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